Navigation Links
ThromboGenics Announces Half Year Results 2008
Date:8/28/2008

r patients.

The first Phase l study showed that TB-403 was safe and well tolerated,

with a pharmacokinetic profile which would allow it to be developed as

a treatment for cancer. TB-403 has moved into a Phase Ib trial. This

study will look at the tolerability, pharmacokinetics and

pharmacodynamics of TB-403 in patients with advanced cancer.

- Microplasmin: Positive results announced in Phase II

clinical trials for ophthalmic indications. Positive results were

reported in ThromboGenics' Phase IIb MIVI III trial in patients with a

number of back of the eye conditions. The trial showed that the most

effective dose of microplasmin studied (125 micro g) was able to

resolve the underlying disease in approximately 30% of patients and

consequently achieved the avoidance of surgical intervention in those

patients.

Further positive six month follow-up results from the Phase IIa MIVI IIT trial, designed to evaluate both the safety and efficacy of microplasmin injection for the treatment of vitreomacular traction, were presented at the Euretina Congress in Vienna, Austria in June.

Investor Highlights

ThromboGenics has continued to work to broaden the Company's shareholder base. In July, ThromboGenics announced the acquisition of an 8% stake in the Company by a group of private investors based in Belgium in a transaction coordinated by Petercam. Their stake was purchased from Biggar Limited, a charitable foundation that is ThromboGenics' largest shareholder. Biggar intends to remain an important shareholder in ThromboGenics for the long term.

Financial Summary

- In the first six months of 2008, revenue amounted to EUR30.3

million. This much higher level of revenue is due to Roche's upfront

payment following the signed co-development deal on TB-403. Operating

expenses were EUR13.0 million in the first half, the majority of which

were due
'/>"/>

SOURCE ThromboGenics NV
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. ThromboGenics Appoints Dr. Patrik De Haes as Chief Executive Officer
2. ThromboGenics Announces Private Investors Acquire 8% Stake in the Company
3. ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
4. ThromboGenics N.V. - Business Update
5. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
6. ThromboGenics Announces 2007 Full Year Results
7. ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
8. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
9. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
10. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
11. ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... , March 27, 2015  Peter Walter was chosen ... for his pioneering work on how proteins are transported ... a regulatory mechanism that cells use to handle stress ... is a professor of biochemistry at the University of ... treating a range of human diseases related to defective ...
(Date:3/27/2015)... March 27, 2015 Governor Andrew M. ... period for 43North - the world’s largest business idea ... grand prize of $1 million, six $500,000 awards and ... the world to compete for prizes that will turn ... the Western New York region. , "Last year's ...
(Date:3/26/2015)... 2015 The Market Element LLC, a ... alliance with Designing Gig LLC to provide website design, ... , “Forging this alliance with Designing Gig represents a ... extend a comprehensive, end-to-end, digital solution for our clients, ... said Chuck Miller, president of The Market Element. “For ...
(Date:3/26/2015)... , March 26, 2015 ... a global clinical research organization , ... a definitive agreement to acquire all of ... ("QSI"), a leading provider of specialized pharmacovigilance ... to the collection, detection, assessment, monitoring, and ...
Breaking Biology Technology:German-born cell biologist Peter Walter wins the 2015 Vilcek Prize in Biomedical Science 2German-born cell biologist Peter Walter wins the 2015 Vilcek Prize in Biomedical Science 3Governor Andrew M. Cuomo Anounces Launch of Year Two of World's Largest Business Idea Competition and Opening of New Incubator Space in Buffalo, New York 2Governor Andrew M. Cuomo Anounces Launch of Year Two of World's Largest Business Idea Competition and Opening of New Incubator Space in Buffalo, New York 3Governor Andrew M. Cuomo Anounces Launch of Year Two of World's Largest Business Idea Competition and Opening of New Incubator Space in Buffalo, New York 4Governor Andrew M. Cuomo Anounces Launch of Year Two of World's Largest Business Idea Competition and Opening of New Incubator Space in Buffalo, New York 5The Market Element LLC and Designing Gig LLC Form Strategic Alliance 2PAREXEL Announces Execution of Definitive Agreement to Acquire Quantum Solutions India, Strengthening Leadership In Pharmacovigilance Services 2PAREXEL Announces Execution of Definitive Agreement to Acquire Quantum Solutions India, Strengthening Leadership In Pharmacovigilance Services 3PAREXEL Announces Execution of Definitive Agreement to Acquire Quantum Solutions India, Strengthening Leadership In Pharmacovigilance Services 4
... who led the technology solutions firm Fiserv through ... executives who will be inducted this month into the Wisconsin ... and chief operating officer from 1984 to 1999, when he ... relatively small private business to a publicly traded company reporting ...
... Modern developments in technology have provided people with ... and cell phones with digital audio capabilities. Technology ... have been considered fantasy 10 years ago are ... environment, companies must consider and understand how technology ...
... Sen. Ted Kanavas is taking aim at a series ... Gov. Jim Doyle . The latest target is an increase in ... revenue. , ,Kanavas, who has proposed tax reductions as part of ... be portrayed as a tax on business and not the consumer, ...
Cached Biology Technology:Making deals with evolving technologies in mind 2Making deals with evolving technologies in mind 3Making deals with evolving technologies in mind 4Making deals with evolving technologies in mind 5
(Date:3/10/2015)... 10, 2015  Continuing its 167-year history of offering ... introduces The Eye Scanning Password Authenticator , a ... to secure websites or sensitive data. Employing ... international borders, the device has a small camera that ... the iris, converting them into an encrypted ID that ...
(Date:3/5/2015)... , March 5, 2015 In ... percent of companies already using these solutions and 42 percent ... Of the latter, approximately 25 percent of the companies will ... While the majority of companies in the region are ... that the hybrid model will command significant attention in the ...
(Date:3/2/2015)... HUNTSVILLE, Ala. , March 2, 2015 /PRNewswire/ ... transaction processing. Data protection company Tharon Rankins Enterprises ... product that provides an ultra-safe way for businesses ... as their financial transactions. Beconux ... by Tharon Rankins Enterprises. Functioning similarly to an ...
Breaking Biology News(10 mins):Hammacher Schlemmer Introduces The Eye Scanning Password Authenticator 2Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 2Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 3Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 4Personal Data Protection Company Launches New Product 2
... therapies often succeed at initially eliminating the bulk ... but are eventually thwarted because they cannot eliminate ... cancer stem cells, which ultimately become the source ... by scientists at the University of Pittsburgh School ...
... New research from Colorado State University shows that the ... circadian -- or daily -- rhythms. The study, publishing ... current theory that only 10 percent to 15 percent ... scientists have long known that circadian rhythms regulate the ...
... temples and cultivated for its wood and cottony fibers, ... biologists have clung to for decades: the notion that ... continents were connected 96 million years ago. , Research ... colleagues shows that kapok---and perhaps other rainforest--trees colonized Africa ...
Cached Biology News:Cancer stem cells similar to normal stem cells can thwart anti-cancer agents 2Research finds that circadian rhythms dominate all life functions 2Research finds that circadian rhythms dominate all life functions 3The kapok connection -- Study explains rainforest similarities 2
UGT1A7 (E-15)...
Canine Aortic Smooth Muscle Cells (CnAOSMC) (>500,000 cells)...
... the third cytoplasmic loop of human D ... The immunizing peptide has 79% homology with ... form: Solution in phosphate buffered saline, pH ... method: IHC (p). Titertest values: immunohistochemistry ...
... Hot Start Taq Monoclonal ... before the onset of ... amplification and primer-dimer formation. ... raised, the antibody is ...
Biology Products: